Practice variation in Aspergillus prophylaxis and treatment among lung transplant centers: A national survey

Transplant Infectious Disease

Volumn 17, Issue 1, 2015, Pages 14-20

  He, S Y ^a   Makhzoumi, Z H ^a   Singer, J P ^a   Chin Hong, P V ^a   Arron, S T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antifungal prophylaxis; Aspergillus colonization; Aspergillus prophylaxis; Invasive aspergillosis; Lung transplant recipients; Lung transplantation; Squamous cell carcinoma

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ECHINOCANDIN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ADMINISTRATIVE PERSONNEL; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANCER SCREENING; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DERMATOLOGIST; DOCTOR PATIENT RELATION; DRUG COST; FUNGAL COLONIZATION; FUNGUS CULTURE; HEALTH CARE SURVEY; HUMAN; INFECTION PREVENTION; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SKIN CANCER; SURGICAL APPROACH; TREATMENT DURATION; UNITED STATES; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; ASPERGILLOSIS; ASPERGILLUS; DRUG EFFECTS; PRE-EXPOSURE PROPHYLAXIS; QUESTIONNAIRE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CROSS-SECTIONAL STUDIES; HUMANS; LUNG TRANSPLANTATION; PRE-EXPOSURE PROPHYLAXIS; SURVEYS AND QUESTIONNAIRES; UNITED STATES; VORICONAZOLE;

EID: 84923253842     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12337     Document Type: Article

References (23)

1. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012; 31 (10): 1073-1086.
2. Minari A, Husni R, Avery RK, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002; 4 (4): 195-200.
3. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003; 22 (3): 258-266.
4. Gordon SM, Avery RK. Aspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategies. Transpl Infect Dis 2001; 3 (3): 161-167.
5. Sole A, Morant P, Salavert M, Peman J, Morales P. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 2005; 11 (5): 359-365.
6. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18 (1): 44-69.
7. Neoh CF, Snell GI, Kotsimbos T, et al. Antifungal prophylaxis in lung transplantation-a world-wide survey. Am J Transplant 2011; 11 (2): 361-366.
8. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6 (12): 3008-3016.
9. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81 (3): 320-326.
10. Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97 (2): 135-144.
11. Borro JM, Sole A, de la Torre M, et al. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc 2008; 40 (9): 3090-3093.
12. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34 (5): 563-571.
13. Drew RH, Dodds Ashley E, Benjamin DK Jr, Duane Davis R, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77 (2): 232-237.
14. Hamacher J, Spiliopoulos A, Kurt AM, Nicod LP. Pre-emptive therapy with azoles in lung transplant patients. Geneva Lung Transplantation Group. Eur Respir J 1999; 13 (1): 180-186.
15. Mattner F, Chaberny IF, Weissbrodt H, et al. [Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole]. Mycoses 2005; 48 (Suppl 1): 51-55.
16. Cadena J, Levine DJ, Angel LF, et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant 2009; 9 (9): 2085-2091.
17. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46 (3): 327-360.
18. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347 (6): 408-415.
19. Singh N, Husain S, and AST Infectious Disease Community of Practice. Aspergillosis in solid organ transplantation. Am J Transplant 2013; 13 (Suppl 4): 228-241.
20. Zwald FO, Spratt M, Lemos BD, et al. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. Dermatol Surg 2012; 38 (8): 1369-1374.
21. Singer JP, Boker A, Metchnikoff C, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant 2012; 31 (7): 694-699.
22. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000; 143 (3): 513-519.
23. Dummer JS, Lazariashvilli N, Barnes J, Ninan M, Milstone AP. A survey of anti-fungal management in lung transplantation. J Heart Lung Transplant 2004; 23 (12): 1376-1381.